To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT04445714

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04445714
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04445714. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-07 (actual); primary completion 2023-03-14 (actual). Results posted on 2024-11-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
dapagliflozin and saxagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04445714
Content hash
73513951f0e7e651bc55d9ba7d80c1abe5b7df16f67da3e4effada946fcd9b02